SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01717404

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation

To understand if Mexiletine will restores normal colonic motility in a patient with irritable bowel syndrome - constipation (IBS-C) and a genetic mutation in SCN5A.

NCT01717404 IBS
MeSH: Irritable Bowel Syndrome

1 Interventions

Name: Mexiletine

Description: 6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects

Type: Drug

Mexiletine


Primary Outcomes

Description: Colon transit will be measured using validated scintigraphy methods conducted in our Clinical Research Unit (CRU).[17, 18] The participant will ingest a Tc-99m labeled sulfur colloid in egg to be used as a stomach marker and ln-111 chloride bound to activated charcoal enclosed in a methacrylate-coated capsule to measure colonic transit.

Measure: change in the 48 hour Colon Transit

Time: Baseline to 10 days

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 A997T

Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation. --- A997T ---

18] The participant will ingest a Tc-99m labeled sulfur colloid in egg to be used as a stomach marker and ln-111 chloride bound to activated charcoal enclosed in a methacrylate-coated capsule to measure colonic transit.. Inclusion Criteria: - Established IBS diagnosis with a known A997T mutation in NaV1.5T --- A997T ---

Patient is currently not on any of these medications Inclusion Criteria: - Established IBS diagnosis with a known A997T mutation in NaV1.5T --- A997T ---



HPO Nodes